Medical aesthetic device maker Venus Concept's Q3 revenue misses

Reuters

2025/11/13

Medical aesthetic device maker <a href="https://laohu8.com/S/VERO">Venus Concept</a>'s Q3 revenue misses

Overview

Venus Concept Q3 2025 revenue down 8% yr/yr, missing analyst expectations
Net loss widened to $22.5 mln in Q3, compared to $9.3 mln last year
Company completed debt-to-equity exchange, reducing debt by 24%

Outlook

Company is not providing financial guidance for fiscal year 2025
Company targets sequential growth in Q4 with Venus NOVA launch
Company faces challenges in closing Venus Hair Business sale

Result Drivers

EBD STABILIZATION - Venus Concept reports signs of stabilization in energy-based device revenues
HAIR BUSINESS DELAY - Decline in Venus Hair Business revenue due to delay in pending sale
VENUS NOVA LAUNCH - FDA clearance received for Venus NOVA, expected to drive future growth

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue	Miss	$13.8 mln	$14.48 mln (1 Analyst)
Q3 EPS		-$12.14
Q3 Net Income		-$22.50 mln
Q3 Adjusted EBITDA		-$7.80 mln
Q3 Gross Margin		64.00%
Q3 Operating Income		-$9.50 mln

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Press Release: ID:nGNX3vylml

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2583562150"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583562150\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583562150?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 20:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583562150","market":"nz","top_or_hot":-1,"title":"Medical aesthetic device maker Venus Concept's Q3 revenue misses","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Medical aesthetic device maker <a href=\"https://laohu8.com/S/VERO\">Venus Concept</a>'s Q3 revenue misses</title></head><body><p><span>Overview</span></p><ul><li><p>Venus Concept Q3 2025 revenue down 8% yr/yr, missing analyst expectations</p></li><li><p>Net loss widened to $22.5 mln in Q3, compared to $9.3 mln last year</p></li><li><p>Company completed debt-to-equity exchange, reducing debt by 24%</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company is not providing financial guidance for fiscal year 2025</p></li><li><p>Company targets sequential growth in Q4 with Venus NOVA launch</p></li><li><p>Company faces challenges in closing Venus Hair Business sale</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>EBD STABILIZATION - Venus Concept reports signs of stabilization in energy-based device revenues</p></li><li><p>HAIR BUSINESS DELAY - Decline in Venus Hair Business revenue due to delay in pending sale</p></li><li><p>VENUS NOVA LAUNCH - FDA clearance received for Venus NOVA, expected to drive future growth</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Miss</p></td><td><p>$13.8 mln</p></td><td><p>$14.48 mln (1 Analyst)</p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$12.14</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$22.50 mln</p></td><td></td></tr><tr><td><p>Q3 Adjusted EBITDA</p></td><td></td><td><p>-$7.80 mln</p></td><td></td></tr><tr><td><p>Q3 Gross Margin</p></td><td></td><td><p>64.00%</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$9.50 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy.\"</p></li></ul><p>Press Release: <span>ID:nGNX3vylml</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medical aesthetic device maker Venus Concept's Q3 revenue misses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedical aesthetic device maker Venus Concept's Q3 revenue misses\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-13 20:11</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Medical aesthetic device maker <a href=\"https://laohu8.com/S/VERO\">Venus Concept</a>'s Q3 revenue misses</title></head><body><p><span>Overview</span></p><ul><li><p>Venus Concept Q3 2025 revenue down 8% yr/yr, missing analyst expectations</p></li><li><p>Net loss widened to $22.5 mln in Q3, compared to $9.3 mln last year</p></li><li><p>Company completed debt-to-equity exchange, reducing debt by 24%</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company is not providing financial guidance for fiscal year 2025</p></li><li><p>Company targets sequential growth in Q4 with Venus NOVA launch</p></li><li><p>Company faces challenges in closing Venus Hair Business sale</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>EBD STABILIZATION - Venus Concept reports signs of stabilization in energy-based device revenues</p></li><li><p>HAIR BUSINESS DELAY - Decline in Venus Hair Business revenue due to delay in pending sale</p></li><li><p>VENUS NOVA LAUNCH - FDA clearance received for Venus NOVA, expected to drive future growth</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Miss</p></td><td><p>$13.8 mln</p></td><td><p>$14.48 mln (1 Analyst)</p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$12.14</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$22.50 mln</p></td><td></td></tr><tr><td><p>Q3 Adjusted EBITDA</p></td><td></td><td><p>-$7.80 mln</p></td><td></td></tr><tr><td><p>Q3 Gross Margin</p></td><td></td><td><p>64.00%</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$9.50 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy.\"</p></li></ul><p>Press Release: <span>ID:nGNX3vylml</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"醫療保健設備","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP0GA:1","article_id":"2583562150","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583562150","pubTimestamp":1763035867,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Medical aesthetic device maker Venus Concept's Q3 revenue missesOverviewVenus Concept Q3 2025 revenue down 8% yr/yr, missing analyst expectationsNet loss widened to $22.5 mln in Q3, compared to $9.3 m","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","VERO":"Venus Concept Inc."},"translate_title":"医美设备制造商Venus Concept第三季度营收未达预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VERO":0.9},"content_text":"Medical aesthetic device maker Venus Concept's Q3 revenue missesOverviewVenus Concept Q3 2025 revenue down 8% yr/yr, missing analyst expectationsNet loss widened to $22.5 mln in Q3, compared to $9.3 mln last yearCompany completed debt-to-equity exchange, reducing debt by 24%OutlookCompany is not providing financial guidance for fiscal year 2025Company targets sequential growth in Q4 with Venus NOVA launchCompany faces challenges in closing Venus Hair Business saleResult DriversEBD STABILIZATION - Venus Concept reports signs of stabilization in energy-based device revenuesHAIR BUSINESS DELAY - Decline in Venus Hair Business revenue due to delay in pending saleVENUS NOVA LAUNCH - FDA clearance received for Venus NOVA, expected to drive future growthKey DetailsMetricBeat/MissActualConsensus EstimateQ3 RevenueMiss$13.8 mln$14.48 mln (1 Analyst)Q3 EPS-$12.14Q3 Net Income-$22.50 mlnQ3 Adjusted EBITDA-$7.80 mlnQ3 Gross Margin64.00%Q3 Operating Income-$9.50 mlnAnalyst CoverageThe current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the advanced medical equipment & technology peer group is \"buy.\"Press Release: ID:nGNX3vylmlFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}